Novo Nordisk

• GLP-1 drugs are driving higher sales for Eli Lilly and Novo Nordisk

  Sales of Mounjaro, Eli Lilly’s diabetes drug, rose 91 per cent in the second quarter of the year to US$9.94 billion, well above analysts' expectations.

  Health

  Aug 5
  
• Novo Nordisk says generic Ozempic, Wegovy will slow sales in Canada

  Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result in more generics and hurt sales.

  Health

  Feb 4
  
• Advertisement
• Health Canada approves 1st GLP-1 daily pill. Here’s who can take it

  The once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a statement Monday.

  Canada

  Jan 12
• Advertisement
• Wegovy weight loss pill is now available for sale in U.S.

  The pill was approved by the U.S. Food and Drug Administration last month, a boon to Novo Nordisk as it looks to regain ground lost to U.S. rival Eli Lilly.

  Health

  Jan 6
• U.S. FDA approves Wegovy weight-loss pill in industry first

  The approval gives Novo Nordisk a leg up in the race to market a potent oral medication for shedding pounds as it looks to regain lost ground from rival Eli Lilly.

  Health

  Dec 22, 2025
• Wegovy won’t be in Canadian public drug plans as Novo Nordisk refuses talks

  Negotiations that could have led to coverage for weight-loss drug Wegovy under Canadian public health plans are not moving forward.

  Health

  Dec 3, 2025
• Ozempic, Wegovy makers Novo Nordisk announce 9K layoffs in restructuring

  Ozempic and Wegovy maker Novo Nordisk says it will layoff about 9,000 employees of its global workforce as it restructures in an attempt to fend off competition.

  World

  Sep 10, 2025
• Ozempic, Wegovy shortages are resolved in the U.S.: FDA

  The drugmaker Novo Nordisk can meet present and future demand in the U.S. for its drugs including Ozempic and Wegovy, the U.S. Food and Drug Administration said.

  Health

  Feb 21, 2025
• Advertisement
• Wegovy approved in Canada to combat risk of non fatal-heart attack

  Health Canada has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults.

  Health

  Nov 27, 2024
• Advertisement
• Wegovy set to launch in Canada. What to know about the weight-loss drug

  Wegovy can also be prescribed to patients who are significantly overweight and have at least one related medical condition such as high blood pressure and Type 2 diabetes.

  Health

  May 2, 2024